Skip to main content

Advertisement

Table 3 Prognostic factors of OS of patients with DLBCL

From: Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma

  Univariate analysis Multivariate analysis1
  P HR (95%CI) P HR (95%CI)
MYC EC 0.003 4.694 (1.697–12.988) 0.002 8.068 (2.145–30.348)
MYC R 0.015 3.831 (1.302–11.277) 0.028 8.005 (1.248–51.359)
MYC expression 0.290 1.590 (0.674–3.752) 0.956 1.035 (0.307–3.491)
BCL2 EC 0.037 2.819 (1.063–7.472) 0.172 2.901 (0.629–13.373)
BCL2 R 0.180 2.224 (0.691–7.155) 0.106 0.089 (0.005–1.676)
BCL2 expression 0.390 1.614 (0.542–4.806) 0.624 0.696 (0.163–2.966)
BCL6 EC 0.517 1.461 (0.465–4.592) 0.434 1.683 (0.457–6.195)
BCL6 R 0.039 2.724 (1.049–7.069) 0.550 1.454 (0.426–4.962)
BCL6 expression 0.585 0.768 (0.297–1.981) 0.813 1.174 (0.310–4.446)
Atypical DHL/THL 0.001 9.054 (2.549–32.167) 0.385 2.841 (0.269–29.957)
DHL/THL 0.004 7.011 (1.866–26.342) 0.463 3.111 (0.150–64.521)
DEL 0.740 1.228 (0.366–4.124) 0.825 0.809 (0.123–5.304)
Age 0.860 0.930 (0.417–2.077) 0.442 2.167 (0.301–15.592)
R-CHOP vs R-CHOPE & R-EPOCH 0.731 0.840 (0.310–2.273) 0.080 0.266 (0.061–1.169)
IPI ≥ 3 0.021 3.618 (1.215–10.770) 0.323 0.223 (0.011–4.367)
Marrow involvement 0.007 3.463 (1.415–8.475) 0.011 4.163 (1.436–12.453)
Ann Arbor stage > 2 0.044 7.926 (1.061–59.198) 0.279 3.704(0.345–39.721)
Extranodal sites ≥2 0.044 2.807(1.027–7.678) 0.599 0.603(0.091–3.977)
Elevated LDH 0.050 2.610(0.999–6.819) 0.260 2.470(0.512–11.920)
  1. DLBCL Diffuse large B-cell lymphoma, EC extra copies, R rearrangement, DHL double hit lymphoma, THL triple hit lymphoma, DEL double expressor lymphoma, IPI international prognostic index, LDH lactate dehydrogenase